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Purpose: A 2-gene, urine based molecular test that combines mRNA biomarkers
with clinical factors can risk stratify patients for clinically significant prostate
cancer. To ensure the generalizability of assay results we optimized and vali-
dated the clinical model for men with serum prostate specific antigen less than
10 ng/ml who were undergoing initial prostate biopsy.
Materials and Methods: Urine samples were collected from 1,955 men from The
Netherlands, France and Germany prior to an initial prostate biopsy and study
subjects were divided into training and validation cohorts. Urinary HOXC6 and
DLX1 mRNA levels were quantified and RNA results were then combined with
other risk factors in a clinical model optimized to detect ISUP (International
Society of Urological Pathology) Grade Group 2 or greater prostate cancer in men
with prostate specific antigen less than 10 ng/ml. Results in the validation cohort
were compared with the PCPTRC (Prostate Cancer Prevention Trial Risk
Calculator), version 2.0.
Results: The optimal clinical model included urinary HOXC6 and DLX1 mRNA
levels, patient age, digital rectal examination and prostate specific antigen
density (serum prostate specific antigen/prostate volume). In the 715 valida-
tion cohort subjects with prostate specific antigen less than 10 ng/ml the AUC
was 0.82 with 89% sensitivity, 53% specificity and 95% negative predictive
value. The PCPTRC AUC was 0.70. The full validation cohort of 916 men
including all prostate specific antigen levels yielded an AUC of 0.85 with 93%
sensitivity, 47% specificity and 95% negative predictive value. The PCPTRC
AUC was 0.76.
Conclusions: The 2-gene based urine assay, which is optimized for biopsy na€ıve
patients with serum prostate specific antigen less than 10 ng/ml, demonstrated
high sensitivity and negative predictive value to detect clinically significant
prostate cancer. These data support using the test to help guide initial prostate
biopsy decisions.




DCA [ decision curve analysis
DRE [ digital rectal examination
GG [ International Society of
Urological Pathology Grade Group
mpMRI [ multiparametric mag-
netic resonance imaging
NPV [ negative predictive value
PCa [ prostate cancer
PCPTRC [ Prostate Cancer Pre-
vention Trial Risk Calculator,
version 2.0
PSA [ prostate specific antigen
PV [ prostate volume
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THERE is a persistent unmet diagnostic need for bet-
ter methods to identify clinically significant PCa.
Despite substantial evidence of the survival benefit
associated with the treatment of intermediate and
high risk, early stage disease,1e4 the low specificity of
PSA screening has led to excess prostate biopsies and
over detection of lower risk cancers,5,6 treatment of
which lacks proven benefit.7,8 Prostate biopsy pro-
cedures and interventional cancer treatment may
carry significant risks, especially in patients with
comorbidities.9,10 PCa specific biomarkers used in
conjunction with PSA and other clinical risk factors11
can improve the detection of PCa with specific
aggressive features such as Gleason score 7 (GG2) or
higher grade, thereby helping to maximize the can-
cer survival benefit while also avoiding prostate bi-
opsies which would detect indolent or no PCa.
A 2-gene urine based molecular test targeting
mRNA known to be overexpressed in aggressive
PCa, the cell proliferation gene HOXC6 and the
progression gene DLX1, has been validated for the
detection of GG2 and higher PCa.12,13 Urinary
HOXC6 and DLX1 mRNA levels are measured
following DRE and the RNA results are combined
with clinical risk factors to determine the individ-
ualized patient risk of GG2 or higher PCa histopa-
thology at a subsequent biopsy.13 The 2-gene test
was clinically validated for the detection of GG2 or
greater PCa in a prospective multicenter cohort of
386 subjects, including 342 (89%) undergoing initial
biopsy and 44 (11%) with prior PCa negative bi-
opsies, and the test had 98% NPV.13 Analytical
validation studies have demonstrated the robust-
ness and reproducibility of the 2-gene urine test
results.14 Risk scores have also been associated with
the mpMRI outcome, suggesting a potential role for
identifying the patients most likely to benefit from
mpMRI or for risk stratification following indeter-
minate mpMRI results.15
The cost-effectiveness of the 2-gene test in men with
elevated PSA was assessed in European and American
modeling studies.16,17 In each study using the 2-gene
test decreased prostate biopsy with its associated
over diagnosis and/or overtreatment compared to the
current standard of care, which resulted in cost sav-
ings and increased quality adjusted life years per pa-
tient.16,17 In addition, the impact on initial biopsy
decision making was demonstrated in a multicenter
study of community urology practices in the United
States.18 The initial biopsy rate was fivefold higher in
test positive vs negative patients.
In this multicenter study we optimized the 2-gene
urinary biomarker based clinical model in men with
PSA levels less than 10 ng/ml who were undergoing
initial prostate biopsy. We then validated its clinical




The study population consisted of 1,955 sequentially
enrolled men, including 750 from Radboud University
Medical Centre, Nijmegen, The Netherlands; 762 from
Lyon Sud Hospital, Lyon, France; and 443 from the
Martini-Klinik Prostate Cancer Center, Hamburg,
Germany. These men underwent an initial prostate bi-
opsy for suspected PCa between December 2007 and
December 2014. All subjects underwent extended 10 to
12-core transrectal ultrasound guided biopsy. PV was
determined by ultrasound at biopsy. In 295 of the 1,955
subjects mpMRI was done prior to biopsy to help target
supplemental cores during the transrectal ultrasound
guided procedure. None of these men underwent mpMRI
fusion biopsy.
Subjects were divided into 1,039 in the training cohort
and 916 in the validation cohort. The Dutch training and
validation cohorts were previously described.13 The
French and German cohorts were evenly split by
randomization. Table 1 shows a summary of study popu-
lation demographic and clinical characteristics in the 805
and 715 men in the training and validation cohorts,
respectively, with PSA less than 10 ng/ml as well as the
entire cohort.
Study exclusion criteria were a prior diagnosis of PCa,
medical therapy known to affect serum PSA levels within
6 months prior to urine sample collection, such as finas-
teride (Proscar or Propecia), dutasteride (Avodart),
antiandrogen therapies (Lupron or Eligard), and
invasive treatment of BPH within 6 months of urine
sample collection.
Sample Collection and Processing
Prior to biopsy first catch urine was collected after a
standardized DRE consisting of 3 sweeps per prostatic
lobe. The urine was mixed with a RNA preservative
(Hologic) and stored at e70C. Urine samples were tested
elsewhere with 2-gene reverse transcriptase-polymerase
chain reaction. Laboratory technicians were blinded to
biopsy outcomes.
Briefly, HOXC6 and DLX1 mRNA were quantified
using reverse transcriptase-polymerase chain reaction
and then normalized for prostate RNA recovery using
urinary KLK3 mRNA levels. KLK3 is the gene that en-
codes for PSA. The normalized HOXC6 and DLX1 levels
were combined into a single RNA value, which was then
used with other risk factors in a clinical model, resulting
in a continuous risk score of e6 to 6. To report results the
risk score was then converted to the percent likelihood
that subsequent biopsy would identify GG2 or greater
PCa.13,14
Statistical Analysis
The clinical model was designed to discriminate GG2 or
higher PCa from GG1 or no PCa at biopsy. Model vari-
ables included the urinary RNA value, patient age, PSA
density calculated as serum PSA/prostate volume and the
DRE result (normal or suspicious). Although the AUC
often serves as a metric for clinical performance, only a
small part of the ROC curve is relevant in the initial
prostate biopsy setting, in which the patient risk
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associated with false-negative results is higher than that
of false-positive findings.19 Therefore, we defined the cost
function to optimize the model as the average false-
positive rate (1 e specificity) of the ROC curve interval
between 93% and 96% sensitivity. The coefficients of the 4
variables were exhaustively determined by minimizing
the cost function. To allow for cases in which PV was not
available we generated an alternate model to maintain
similar sensitivity and NPV by allowing variable speci-
ficity. In the absence of PV PSA density was replaced by
serum PSA as a stand-alone variable.
Statistical analyses were performed with R, version
3.4.0 (R Foundation for Statistical Computing, Vienna,
Austria). The clinical performance of RNA biomarkers,
clinical variables and models was assessed based on the
ROC AUC. The 95% CI and AUC comparisons were
determined by the DeLong method as implemented in
the R package pROC.20,21 The Mann-Whitney test was
applied to assess differences in quantitative measure-
ments. The PCPTRC was used for comparison. DCA
was performed in R as previously described.22 Cali-
bration curves were generated in R using the val.prob
function.21,23
RESULTS
Combining Risk Factors to Detect High Grade
Prostate Cancer
Clinical models were developed using 805 training
cohort subjects with serum PSA less than 10 ng/ml
(table 1). This yielded an AUC of 0.80 (95% CI
0.76e0.84). At the optimal risk score cutoff of e2.8
sensitivity was 93%, specificity was 52% and NPV
was 96%. Figure 1 shows the relationship between
the risk score and the likelihood of GG2 or higher
PCa, GG1 PCa and no PCa at biopsy using data on
the full sample set of 1,955 primary biopsies. Higher
risk scores were associated with an increased like-
lihood of GG2-5 PCa at biopsy, providing an
individualized risk assessment to assist with biopsy
decision making.
Clinical Validation
In the training cohort of 805 men with PSA less
than 10 ng/ml the AUC was 0.80 (95% CI
0.76e0.84). At the optimal risk score cutoff of e2.8
sensitivity was 93%, specificity was 52% and NPV
was 96%. The optimized clinical model was applied
to the 715 validation cohort subjects with serum
PSA less than 10 ng/ml. This yielded an AUC of 0.82
(95% CI 0.79e0.86), 89% sensitivity, 53% specificity
and 95% NPV. When PV was omitted from the
model, sensitivity was 87%, specificity was 38% and
NPV was 92%.
Because many clinicians use suspicious DRE re-
sults as a stand-alone indication for biopsy, we also
evaluated performance in subjects with normal
DRE results. Table 2 summarizes performance
Figure 1. Percent probability of GG2 or greater (green curve), no
PCa (blue curve) andGG1 PCa (yellow curve) at biopsy in relation
to risk score. Vertical line at risk score e2.8 represents cutoff
point of overall positive vs negative result.
Table 1. Subject demographic and clinical characteristics in training and validation cohorts
PSA Less Than 10 ng/ml All Subjects
Training Validation Training Validation
No. subjects 805 715 1,039 916
Median age (IQR) 64 (59d68) 64 (59d69) 64 (59d69) 65 (60d70)
Median ng/ml serum PSA (IQR) 5.5 (4.1d6.9) 5.4 (4.1d7.2) 6.2 (4.6d9.4) 6.4 (4.5d9.2)
No. DRE result (%):
Normal 636 (79) 585 (82) 758 (73) 706 (77)
Suspicious 168 (21) 124 (17) 280 (27) 205 (22)
Not available 1 (0.1) 6 (1) 1 (0.1) 6 (1)
No. PCa family history (%):
Yes 126 (16) 110 (15) 148 (14) 130 (14)
No 648 (80) 499 (70) 845 (81) 632 (69)
Not available 31 (4) 106 (15) 46 (4) 154 (17)
Biopsy outcome (%):
No PCa 455 (56.5) 388 (54.3) 518 (49.9) 449 (49.0)
GG1 196 (24.3) 175 (24.5) 239 (23.0) 209 (22.8)
GG2 99 (12.3) 97 (13.6) 145 (14.0) 127 (13.9)
GG3 26 (3.2) 27 (3.8) 54 (5.2) 65 (7.1)
GG4 15 (1.9) 17 (2.4) 38 (3.7) 34 (3.7)
GG5 14 (1.7) 11 (1.5) 45 (4.3) 32 (3.5)
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characteristics in the validation cohort, stratified by
PSA (PSA less than 10 ng/ml or all values) and the
DRE result. For all conditions the NPV was 95%.
The optimized model was also applied to the vali-
dation cohort from the previous clinical validation
study.13 The AUC was 0.88 (0.84e0.92), sensitivity
was 98%, specificity was 42% and NPV was 98%.
Figure 2 shows ROC curves of the optimized clin-
ical model and the PCPTRC in the subject groups. In
validation cohort subjects with PSA less than 10 ng/ml
the AUC was 0.82 (95% CI 0.79e0.86) compared to the
PCPTRC AUC of 0.70 (95% CI 0.65e0.74, p <0.001).
In the entire validation cohort regardless of PSA level
the optimized clinical model AUC was 0.85 (95% CI
0.83e0.88), with 93% sensitivity, 47% specificity and
95% NPV while the PCPTRC AUC was 0.76 (95% CI
0.72e0.80, p <0.001).
To further characterize the optimized model we
analyzed the incremental benefit of the urinary
biomarkers relative to clinical risk factors and
assessed the model calibration. Figure 3 shows
urinary HOXC6 and DLX1 mRNA levels normalized
to KLK3 as the prostate specific control in valida-
tion cohort subjects with no PCa, GG1 PCa, or GG2
or greater PCa at biopsy. For each mRNA the rela-
tive level was significantly higher in men diagnosed
with GG2 or greater PCa vs GG1 PCa (p <0.0001).
DCA was performed using the optimized model
with and without HOXC6 and DLX1 mRNA mea-
surements (fig. 4). The DCA showed a net benefit of
the full model compared to the no RNA model to
detect GG2 or higher PCa while avoiding excess bi-
opsies, particularly at lower risk thresholds. Results
were similar in men with PSA less than 10 ng/ml and
in the full validation cohort (fig. 4).
Figure 5 shows calibration plots of the risk
score and PCPTRC in the full validation cohort of
916 subjects. The optimized model showed good
Table 2. Optimized clinical model performance characteristics in validation cohort stratified by serum PSA and digital rectal
examination results
PSA Less Than 10 ng/ml All PSA Results
All DRE Results Normal DRE Results All DRE Results Normal DRE Results
No. subjects 715 591 916 712
ROC AUC (95% CI) 0.82 (0.79e0.86) 0.80 (0.76e0.85) 0.85 (0.83e0.88) 0.82 (0.78e0.86)
% Sensitivity 89 84 93 89
% Specificity 53 57 47 41
% Pos predictive value 34 29 43 33
Negative predictive value remained constant at 95% across all patient subgroups.
Figure 2. ROC curves of optimized clinical model (red curves) and PCPTRC (blue curves) in 715 validation cohort subjects with PSA less
than 10 ng/ml (A) and full validation cohort of 916 with all PSA levels (B).
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calibration with a slight trend toward overestimating
risk at probabilities below approximately 25%
and underestimating risk at higher probabilities
(fig. 5, A). As a point of reference the risk score
threshold used to determine overall positive vs
negative assay results and determine perfor-
mance characteristics (table 2) corresponded to a
probability of 12%. In contrast, the PCPTRC
consistently underestimated risk in the valida-
tion cohort (fig. 5, B).
To assess the potential impact of the optimized
model on patient treatment the validation cohort of
715 men with PSA less than 10 ng/ml was evaluated
when assuming that assay results were the sole
determinant for the biopsy decision on study. Based
on the patients with negative test results 314 of all
715 biopsies (44%) and 297 of 563 biopsies (53%)
which identified GG1 or no PCa would have been
avoided or delayed. In patients with negative test
results who were found to have PCa at biopsy 61 of
175 (35%) with GG1 PCa, 12 of 97 (12%) with GG2, 4
of 27 (15%) with GG3, 1 of 17 (5.9%) with GG4 and
0 of 11 (0%) with GG5 may have had a delayed
diagnosis. In the overall validation cohort 17 of 715
men (2.4%) had negative test results and were
diagnosed with GG2 or greater PCa at biopsy.
Figure 3. Box plots of urinary HOXC6 (A) and DLX1 (B) mRNA in subjects with no PCa, low grade PCa or clinically significant PCa at
biopsy. Horizontal line indicates median. x indicates average.
Figure 4. Decision curve analysis of full clinical model (red curves) vs clinical model without RNA markers (blue curves) in validation
cohort subjects with PSA less than 10 ng/mL (A) and in full validation cohort (B). Gray curve: all subjects have GG2 or higher PCa,
horizontal line: no subjects have GG2 or higher PCa.
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DISCUSSION
Accurately identifying clinically significant PCa re-
mains one of the key unmet needs in the diagnosis
and management of this pervasive disease. An
approach to this dilemma is to use PCa specific
biomarkers which can be combined with clinical risk
factors to improve the detection of GG2 and higher
PCa. We previously described the development and
validation of the 2-gene urinary biomarker based
clinical model to discriminate GG2 and higher PCa
from GG1 and benign disease in men undergoing
prostate biopsy.13 In this study we confirmed and
expanded these findings in a larger, multinational
population of men who were undergoing an initial
prostate biopsy with an emphasis on patients with
PSA less than 10 ng/ml.
The clinical model was optimized to maintain
high sensitivity and NPV to detect GG2 or greater
PCa in the initial biopsy setting. In the validation
cohort of 715 subjects with PSA less than 10 ng/ml
the AUC was 0.82, sensitivity was 89%, specificity
was 53% and NPV was 95%. If the 2-gene test had
been used for the initial biopsy decision, 53% of
excess biopsies (ie biopsies which would have iden-
tified GG1 or no cancer) could have been avoided
and a diagnosis of clinically significant PCa may
have been delayed in 5% of patients.
Because PV is not always available in biopsy
na€ıve men, the model was designed to compensate
and yielded a NPV of 92% when this parameter was
not included. In all 916 validation cohort subjects
with any PSA level sensitivity was 93%, specificity
was 47% and NPV was 95%. The NPV of 95% was
maintained when analysis was limited to men with
normal DRE results, who therefore might be more
likely to benefit from additional testing. Impor-
tantly, when the optimized model was applied to the
validation cohort in the initial validation study,13
results were equivalent to previously reported
findings with 98% NPV. Taken together these re-
sults demonstrate the robustness of the clinical
model across different patient cohorts.
Characterization of the optimized model confirmed
that HOXC6 and DLX1 mRNA measurements pro-
vide a significant improvement in test performance
compared to clinical risk factors alone. Urinary
levels of the individual mRNAs were significantly
associated with clinically significant PCa, consistent
with previous reports.13,14 DCA demonstrated net
benefit of the RNA biomarkers, particularly at lower
risk thresholds where the test may be most useful in
clinical practice. Finally, the optimized clinical
model was found to be well-calibrated for predicting
the probability of detecting GG2 or higher PCa at
biopsy.
Several other options are available to clinicians to
help guide initial biopsy decisions. Increasingly
mpMRI is performed for PCa detection. However, a
recent meta-analysis highlighted mpMRI vari-
ability with 64% to 88% NPVs,24 lower than in our
report. In addition, the AUA (American Urological
Association) currently recommends mpMRI only in
the repeat biopsy setting.25
Blood based PSA derivative assays and other
urinary markers have shown potential to improve
the prediction of the initial biopsy outcome. The
Figure 5. Calibration plots of risk score (A) and PCPTRC (B) in validation cohort. Gray curve indicates ideal. Black curve indicates logistic
calibration. Dotted curve indicates nonparametric data.
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results of this clinical validation compare favorably
with those of published studies using these other
methodologies.11
The strengths of this multicenter validation
study include the relatively large training and
validation cohorts, and the assessment of clinical
performance in all patients with an initial biopsy
using a model optimized for men with PSA less than
10 ng/ml. Limitations include the fact that the study
was retrospective and there was a lack of racial/
ethnic background information on the study popu-
lation, which was presumed to be primarily Cauca-
sian. This likely does not reflect the diversity of
potential patients who undergo an initial biopsy in
the United States.
CONCLUSIONS
The 2-gene urine biomarker based assay was opti-
mized for biopsy na€ıve patients with serum PSA less
than 10 ng/ml and clinically validated in a multicenter
study. The 2-gene test demonstrated high sensitivity
and NPV to detect GG2 or greater PCa with the po-
tential to improve the detection of clinically significant
disease by avoiding approximately half of excess
prostate biopsies. These data support the use of this
test to help guide initial prostate biopsy decisions.
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EDITORIAL COMMENT
In the United States a shotgun approach to screening
and treatment led to a 52% reduction in age
adjusted prostate cancer specific mortality but this
was tempered by the pandemic of men who never
needed to be diagnosed, let alone treated. This
mRNA urine test (SelectMDx) is scientifically
sound, now has 2 validation studies and is capable
of decreasing the biopsy rate by 40% to 50% while
delaying the diagnosis in 2% to 5% of men known
to have GG2 or greater (Gleason 7 or greater
cancer). Interestingly, similar to other biomarkers,
no consistent relationship was observed between
the biomarker risk score and GG1 (Gleason 6) (fig.
1 in article), further evidence corroborating its
inert nature.
About 10 biomarkers are available or in develop-
ment with similar intent, of which most are costly. It
is a busy clinical space but collectively a much
welcomed advance. At a bare minimum when urolo-
gists screen for prostate cancer, they should capi-
talize on the powerful information embedded in
inexpensive tests such as total PSA, percent free
PSA, PSA density and digital rectal examination.
Use of secondary markers (magnetic resonance im-
aging, or urine, blood or tissue based markers) is
data based and sensible but pricey. Reflex use in all
men is mindless and should be discouraged. When
used appropriately, added value is provided, partic-
ularly when scores are low or high.
Scott Eggener
Departments of Surgery and Radiology
University of Chicago Medicine
Chicago, Illinois
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